Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 171

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 171
---
 stock subject to the ISO over the exercise price is a preference items for AMT purposes.

A U.S. Participant generally does not recognize income upon the grant of a SAR. The U.S. Participant recognizes ordinary compensation income upon exercise of the SAR equal to the increase in the value of the underlying shares, and we will generally be entitled to a deduction for such amount.

A U.S. Participant generally does not recognize income on the receipt of a performance stock award, performance unit award, restricted stock unit award or dividend equivalent rights award until a cash payment or a distribution of shares of common stock is received thereby. At such time, the U.S. Participant recognizes ordinary compensation income equal to the excess, if any, of the fair market value of the shares of common stock or cash received over any amount paid for the shares of common stock thereby, and Company will generally be entitled to deduct such amount at such time.

A U.S. Participant who receives a restricted stock award generally recognizes ordinary compensation income equal to the excess, if any, of the fair market value of such common stock at the time the restriction lapses over any amount paid thereby for the common stock. Alternatively, the U.S. Participant may elect to be taxed on the fair market value of such shares of common stock at the time of this grant. Company will generally be entitled to a deduction at the same time and in the same amount as the income that is required to be included by the U.S. Participant.

A U.S. Participant who receives an unrestricted stock award generally recognizes ordinary compensation income equal to the excess, if any, of the fair market value of such common stock on the date of grant. The Company will generally be entitled to a deduction for such amount.

Director Compensation

We intend to use monthly fees and stock option grants to attract and retain qualified candidates to serve on the Board. This compensation reflected the financial condition of the Company. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties to the Company as well as the skill-level required by our members of the Board.

We do not intend to compensate our non-employee directors.

<div align='center'>110</div>

BENEFICIAL OWNERSHIP OF SECURITIES The following table sets forth information as of July 23, 2025 regarding the beneficial ownership of shares of our Common Stock by:

| ● | each person known by us to be the beneficial owner of more than 5% of the outstanding shares of any class of our voting securities; |

| ●